Strong demand for Briumvi in the US.
3 reports, 3 independent
Updated Aug 4
Gone quiet
Reached 2 outlets in its first 24 hours
- Reports
- 3
- Developments
- 3
- Repetition
- 0%
New informationRepeats or wire copies
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
Strong demand for Briumvi in the US.
Who's involved
What this event is mainly aboutHow it developed
Newest first. Tap a step to see who reported it.BRIUMVI aims to remove barriers for patients switching from competing therapies, with analysts comparing its market potential to Nvidia.1 source
Strong demand for Briumvi in the US.1 source
BRIUMVI is TG Therapeutics' flagship product; subcutaneous development aims to expand the addressable market.1 source
Keep exploring
The entities involved
-
TG Therapeutics
a commercial stage biopharmaceutical company
Coverage
Newest first; wire copies grouped- yahoo.com
- ZacksWhy Is TG Therapeutics (TGTX) Up 4.7% Since Last Earnings Report? It has been about a month since the last earnings report for TG Therapeutics (TGTX). Shares have added about 4.7% in that time frame,
- GuruFocus.comTG Therapeutics Inc (TGTX) Q2 2025 Earnings Call Highlights: Robust Revenue Growth and ... Total Revenue: $141.1 million for Q2 2025. US Net Product Revenue: $138.8 million, a 91% increase year-over-